Mannkind Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mannkind Corporation

MNKD 5.590

+0.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Savant	11/5/2021 4:45:08 PM
	of 84

This feasibility study demonstrated that a TI dose -- approximately double the estimated mealtime SC injection dose --provided significant reductions in PPGE without severe hypoglycemia. The maximum mean postprandial glucose decreased from 234 to 186 mg/dL and significant reductions in PPGE were observed from 45 to 120 minutes. Twenty adult participants (= 18 years) with T1D or T2D who were on a stable regimen of basal-bolus insulin therapy were enrolled in this feasibility study. Each subject received an initial dose of TI based on the conversion chart in the current U.S. package insert. At the next visit, subjects were dosed based on doubling the estimated SC injection dose of mealtime insulin and rounding down to the nearest TI cartridge. The protocol specified administering TI doses immediately prior to consuming an identical standardized meal. Capillary blood glucose was measured by CONTOUR meters (Ascensia Diabetes Care in Parsippany, NJ).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next